Última actualización :
28/04/2024
Antibiótico   Oxacillin sodium  
Inyectables
Estabilidad en solucion Estabilidad en mezcla Factores que influyen sobre la estabilidad Compatibilidades Método de inyección Bibliografía Pdf
   Estructura química  

Nombre comercial   Nombre comercial     

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Bactocill Estados Unidos de América
Bioxalin Marruecos
Bristopen Marruecos
Istopen Francia
Lioxac Marruecos
Oxacil Túnez
Oxacilil Brasil
Oxacilina Brasil, Colombia, Ecuador, Marruecos, Rumania, Venezuela
Oxacillin Estados Unidos de América
Oxacip Venezuela
Oxalin Marruecos
Oxamicin Venezuela
Oxanon Brasil
Oxipen Venezuela
Pebenal Venezuela
Staphymicine Marruecos
Bibliografía   Inyectables   Bibliografía : Oxacillin sodium  
Tipo Publicación
13 Periódico Stiles ML, Allen LV.
Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium and tobramycin sulfate in polyvinyl chloride drug reservoirs.
Am J Health-Syst Pharm 1997 ; 54: 1068-1070.
73 Periódico Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
150 Periódico Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
198 Periódico Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
336 Periódico Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409.
337 Periódico Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533.
371 Periódico Thompson DF, Stiles ML, Allen LV, Tu YH.
Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 142-145.
386 Periódico Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358.
397 Periódico Fong PA, Ward J.
Visual compatibility of intravenous famotidine with selected drugs.
Am J Hosp Pharm 1989 ; 46: 125-126.
405 Periódico Nieves-Cordero AL, Luciw HM, Souney PF.
Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1985 ; 42: 1108-1109.
479 Periódico Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966.
496 Periódico Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
576 Periódico Holmes CJ, Ausman RK, Walter CW, Kundsin RB.
Activity of antibiotic admixtures subjected to different freeze-thaw treatments.
Drug Intell Clin Pharm 1980 ; 14: 353-357.
604 Laboratorio Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998
738 Periódico Gardella LA, Kesler H, Amann A, Carter JE.
Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives.
Am J Hosp Pharm 1978 ; 35: 581-584.
999 Periódico Watson D.
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.
JPEN 1985 ; 9: 220-224.
1047 Periódico Souney PF, Colucci RD, Mariani G, Campbell D.
Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1984 ; 41: 323-324.
1057 Periódico Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072 Periódico Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1135 Periódico Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077.
1228 Periódico Allen LV, Stiles ML.
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.
Am J Hosp Pharm 1981 ; 38: 380-381.
1705 Periódico Zhang Y, Trissel LA.
Stability of ampicillin sodium, nafcillin sodium, and oxacillin sodium in autodose system bags.
Int J Pharm Compound 2002 ; 6: 226-229.
1802 Periódico Bell MS, Nolt DH.
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Am J Health-Syst Pharm 2003 ; 60: 193-194.
3227 Periódico Simon B, Hancu G, Gy?resi A.
Application of capillary electrophoresis to the simultaneous determination and stability study of four extensively used penicillin derivatives
Braz J Pharm Sci 2014 ; 50, 3 : 521-527.
3520 Laboratorio Cidomycin - Summary of product Chracteristics.
Sanofi 2011
3529 Laboratorio Ciprofloxacin – Summary of Product Characteristics
Hospira 2013
3549 Laboratorio Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3580 Laboratorio Cytarabine Accord - Résumé des caractéristiques du produit
Accord Healthcare France 2016
3589 Laboratorio Oxacilline PanPharma – Résumé des caractéristiques du produits
PanPharma 2013
3638 Laboratorio Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics
Hospira 2010
3643 Laboratorio Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
Sanofi 2015
3674 Laboratorio Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3813 Periódico Teibel H.M, Knoderer C.A, Nichols K.R.
Compatibility of Vancomycin and Oxacillin During Simulated Y-Site Delivery.
Hosp Pharm 2015 ; 50, 8: 710-713.

  Mentions Légales